“Shedding” light on HER4 signaling in normal and malignant breast tissues

Brockhoff, Gero

doi:10.1016/j.cellsig.2022.110401

Cited by 6 publications

(1 citation statement)

References 118 publications

(158 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HER2 is an oncogenic membrane-spanning receptor of a signaling pathway located in the intracellular and extracellular domains (ECD). HER2 belongs to the family of epidermal growth factor receptor tyrosine kinases known as EGFR or ErbB, encompassing four structurally analogous receptors including HER1, HER2, HER3, and HER4 [20,21]. When HER2 is overexpressed, it generates a rearrangement of the HER family of dimers, leading to a significant augmentation of the HER2-containing heterodimers and homodimers and enabling the HER2 receptor activation by dimerization with another HER family member [22,23].…”

Section: Her2 As An Oncogenic Molecular Drivermentioning

confidence: 99%

Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review

Giffoni de Mello Morais Mata,

Chehade,

Hannouf

et al. 2023

Cancers

View full text Add to dashboard Cite

Background: The overexpression of the human epidermal growth factor receptor 2 (HER2+) accounts for 15–20% of all breast cancer phenotypes. Even after the completion of the standard combination of chemotherapy and trastuzumab, relapse events occur in approximately 15% of cases. The neoadjuvant approach has multiple benefits that include the potential to downgrade staging and convert previously unresectable tumors to operable tumors. In addition, achieving a pathologic complete response (pCR) following preoperative systemic treatment is prognostic of enhanced survival outcomes. Thus, optimal evaluation among the suitable strategies is crucial in deciding which patients should be selected for the neoadjuvant approach. Methods: A literature search was conducted in the Embase, Medline, and Cochrane electronic libraries. Conclusion: The evaluation of tumor and LN staging and, hence, stratifying BC recurrence risk are decisive factors in guiding clinicians to optimize treatment decisions between the neoadjuvant versus adjuvant approaches. For each individual case, it is important to consider the most likely postsurgical outcome, since, if the patient does not obtain pCR following neoadjuvant treatment, they are eligible for adjuvant T-DM1 in the case of residual disease. This review of HER2-positive female BC outlines suitable neoadjuvant and adjuvant systemic treatment strategies for guiding clinical decision making around the selection of an appropriate therapy.

show abstract

Section: Her2 As An Oncogenic Molecular Drivermentioning

confidence: 99%

Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review

Giffoni de Mello Morais Mata,

Chehade,

Hannouf

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

Design, synthesis, graph theoretical analysis and molecular modelling studies of novel substituted quinoline analogues as promising anti-breast cancer agents

Dessai¹,

Dessai²,

Dabholkar³

et al. 2022

Mol Divers

View full text Add to dashboard Cite

A variant in the 5′UTR of ERBB4 is associated with lifespan in Golden Retrievers

Rebhun,

York,

De Graaf

et al. 2023

GeroScience

View full text Add to dashboard Cite

Genome-wide association studies (GWAS) in long-lived human populations have led to identification of variants associated with Alzheimer’s disease and cardiovascular disease, the latter being the most common cause of mortality in people worldwide. In contrast, naturally occurring cancer represents the leading cause of death in pet dogs, and specific breeds like the Golden Retriever (GR) carry up to a 65% cancer-related death rate. We hypothesized that GWAS of long-lived GRs might lead to the identification of genetic variants capable of modifying longevity within this cancer-predisposed breed. A GWAS was performed comparing GR dogs ≥ 14 years to dogs dying prior to age 12 which revealed a significant association to ERBB4, the only member of the epidermal growth factor receptor family capable of serving as both a tumor suppressor gene and an oncogene. No coding variants were identified, however, distinct haplotypes in the 5′UTR were associated with reduced lifespan in two separate populations of GR dogs. When all GR dogs were analyzed together (n = 304), the presence of haplotype 3 was associated with shorter survival (11.8 years vs. 12.8 years, p = 0.024). GRs homozygous for haplotype 3 had the shortest survival, and GRs homozygous for haplotype 1 had the longest survival (11.6 years vs. 13.5 years, p = 0.0008). Sub-analyses revealed that the difference in lifespan for GRs carrying at least 1 copy of haplotype 3 was specific to female dogs (p = 0.009), whereas survival remained significantly different in both male and female GRs homozygous for haplotype 1 or haplotype 3 (p = 0.026 and p = 0.009, respectively). Taken together, these findings implicate a potential role for ERBB4 in GR longevity and provide evidence that within-breed canine lifespan studies could serve as a mechanism to identify favorable or disease-modifying variants important to the axis of aging and cancer.

show abstract

“Shedding” light on HER4 signaling in normal and malignant breast tissues

Cited by 6 publications

References 118 publications

Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review

Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review

Design, synthesis, graph theoretical analysis and molecular modelling studies of novel substituted quinoline analogues as promising anti-breast cancer agents

A variant in the 5′UTR of ERBB4 is associated with lifespan in Golden Retrievers

Contact Info

Product

Resources

About